Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

9 Months Ended

Sep. 30, 2021

5Accrued Expenses

Accrued expenses consist of the following:


	September 30,		December 31,
	2021		2020
Accrued compensation	$	459,060	$	573,479
Accrued interest on preferred members’ interests		188,085		188,085
Accrued professional fees		33,314		8,992
Accrued director fees		46,500		—
Other		16,332		13,548
	$	743,291	$	784,104